DHG Pharmaceutical Joint Stock Company Sustainability Profile
DHG Pharmaceutical Joint Stock Company, commonly referred to as DHG Pharma, is a leading player in the pharmaceutical industry based in Vietnam. Established in 1976, the company has its headquarters in Can Tho and operates extensively across major regions in Vietnam, focusing on the production and distribution of high-quality pharmaceutical products. Specialising in a diverse range of medications, including prescription drugs, over-the-counter products, and herbal medicines, DHG Pharma is renowned for its commitment to innovation and quality. The company has achieved significant milestones, including numerous awards for excellence in manufacturing and product development, solidifying its position as a trusted name in healthcare. With a robust market presence, DHG Pharma continues to expand its reach, contributing to the health and well-being of communities throughout Vietnam and beyond.
DitchCarbon Score
How does DHG Pharmaceutical Joint Stock Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DHG Pharmaceutical Joint Stock Company's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
As of the latest available data, DHG Pharmaceutical Joint Stock Company, headquartered in Vietnam, does not report specific carbon emissions figures. The company is a current subsidiary of Taisho Pharmaceutical Co., Ltd., which may influence its climate strategies and performance metrics. While there are no documented reduction targets or climate pledges from DHG Pharmaceutical, the company is part of a broader industry context that increasingly prioritises sustainability and carbon footprint reduction. The absence of specific emissions data suggests that DHG Pharmaceutical may still be developing its climate commitments or reporting frameworks. Given the lack of direct emissions data, it is essential to note that the company may benefit from initiatives and targets set by its parent company, Taisho Pharmaceutical Co., Ltd. However, specific details regarding these initiatives or any cascading targets from the parent organisation are not provided. In summary, DHG Pharmaceutical Joint Stock Company currently lacks publicly available emissions data and defined climate commitments, reflecting a potential area for future development in sustainability practices within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Scope 1 | 26,236,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 30,028,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is DHG Pharmaceutical Joint Stock Company's Industry?
How Carbon Intensive is DHG Pharmaceutical Joint Stock Company's Location?
DHG Pharmaceutical Joint Stock Company's Scope 3 Categories Breakdown
DHG Pharmaceutical Joint Stock Company's Scope 3 emissions, which decreased by 2% last year and decreased by approximately 2% since 2020, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 74% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
DHG Pharmaceutical Joint Stock Company's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
DHG Pharmaceutical Joint Stock Company has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
